Uncategorized
Jun. 16, 2022 Bioasis Acquires Phase 2 Ready Rare Orphan EGF Assets
Phase 2 ready assets transform Bioasis into a clinical stage company with a multi-asset pipeline focused on rare and orphan drug indications Unique approach to neurodegeneration targeting…
Jun. 14, 2022 Bioasis Announces Filing of Its Fourth Quarter and Fiscal Year-End Financial Statements and MD&A
NEW HAVEN, Conn., June 14, 2022 (GLOBE NEWSWIRE) — BIOASIS TECHNOLOGIES INC. (TSXV:BTI.V; OTCQB:BIOAF), (the “Company” or “Bioasis”), a biopharmaceutical company developing its proprietary xB3 ™…
May. 10, 2022 Bioasis and Neuramedy Enter into Research Collaboration and License Agreement
NEW HAVEN, CONN., U.S.A., May 10, 2022 (GLOBE NEWSWIRE) — BIOASIS TECHNOLOGIES INC.. (TSXV:BTI.V; OTCQB:BIOAF), (the “Company or “Bioasis”) a biopharmaceutical company developing its proprietary…
Apr. 11, 2022 Bioasis Enters Into Research Collaboration With Janssen
NEW HAVEN, CONN., U.S.A., April 11, 2022 (GLOBE NEWSWIRE) — BIOASIS TECHNOLOGIES INC. (TSXV:BTI.V; OTCQB:BIOAF), (the “Company or “Bioasis”), a biopharmaceutical company developing its proprietary…
Mar. 9, 2022 Bioasis to Attend and Present at Upcoming Industry Conference
NEW HAVEN, Conn., March 09, 2022 (GLOBE NEWSWIRE) — BIOASIS TECHNOLOGIES INC. (TSXV:BTI; OTCQB:BIOAF), (the “Company” or “Bioasis”), a biopharmaceutical company developing its proprietary xB3™…
Feb. 17, 2022 Bioasis Announces $200,000 Non-Brokered Private Placement
NEW HAVEN, Conn., Feb. 17, 2022 (GLOBE NEWSWIRE) — BIOASIS TECHNOLOGIES INC. (TSXV:BTI; OTCQB:BIOAF), (the “Company” or “Bioasis”), a biopharmaceutical company developing its proprietary xB3™…
Jan. 20, 2022 Bioasis Announces Filing of Its Quarter and Financial Statements and MD&A for the Period Ending November 30, 2021
NEW HAVEN, Conn., Jan. 20, 2022 (GLOBE NEWSWIRE) — Bioasis Technologies Inc.?(TSX.V:BTI; OTCQB:BIOAF) (the “Company” or “Bioasis”), a biopharmaceutical company developing its proprietary xB3™…
Dec. 16, 2021 Bioasis Announces Annual General Meeting Results
NEW HAVEN, Conn., Dec. 16, 2021 (GLOBE NEWSWIRE) — BIOASIS TECHNOLOGIES INC. (TSXV:BTI; OTCQB:BIOAF), (the “Company” or “Bioasis”), a biopharmaceutical company developing its proprietary xB3™…
Dec. 9, 2021 Bioasis to Attend and Present at Upcoming Industry Conferences
NEW HAVEN, Conn., Dec. 09, 2021 (GLOBE NEWSWIRE) — BIOASIS TECHNOLOGIES INC. (TSXV:BTI; OTCQB:BIOAF), (the “Company” or “Bioasis”), a biopharmaceutical company developing its proprietary xB3™…
Nov. 29, 2021 Bioasis Announces Annual General Meeting Details
NEW HAVEN, Conn., Nov. 29, 2021 (GLOBE NEWSWIRE) — BIOASIS TECHNOLOGIES INC. (TSXV:BTI; OTCQB:BIOAF), (the “Company” or “Bioasis”), a biopharmaceutical company developing its proprietary xB3™…